These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 3055991)
21. [Hyperlipoproteinemia as a factor in the progression of glomerulonephritis with nephrotic syndrome]. Smirnov AV; Sazonets GI; Rakitianskaia IA; Travkina ES Ter Arkh; 1992; 64(11):45-8. PubMed ID: 1293843 [No Abstract] [Full Text] [Related]
22. [Current state of the problem of lipid metabolism in patients with kidney diseases]. Storozhenko AA Klin Med (Mosk); 1973 Oct; 51(10):28-30. PubMed ID: 4787276 [No Abstract] [Full Text] [Related]
25. Atherogenic lipoproteins and human disease: extending concepts beyond the heart to the kidney. Kamanna VS; Bassa BV; Kirschenbaum MA Curr Opin Nephrol Hypertens; 1997 May; 6(3):205-11. PubMed ID: 9263660 [No Abstract] [Full Text] [Related]
26. Circulating antibodies recognising oxidatively-modified low-density lipoproteins in patients with IgA nephropathy, membranous glomerulonephritis and focal glomerulosclerosis. Fornasieri A; Perugini C; Seccia M; Napodano P; D'Amico G; Bellomo G J Nephrol; 2002; 15(4):349-57. PubMed ID: 12243363 [TBL] [Abstract][Full Text] [Related]
27. Immunoexpression of podocyte-associated proteins in acquired human glomerulopathies with nephrotic syndrome. Wagrowska-Danilewicz M; Stasikowska O; Danilewicz M Pol J Pathol; 2006; 57(1):17-21. PubMed ID: 16739878 [TBL] [Abstract][Full Text] [Related]
28. 11-Deoxycorticosterone-induced hypertension, glomerulosclerosis and renal arterial and arteriolar lesions. Shimamura T Jpn J Exp Med; 1988 Oct; 58(5):225-8. PubMed ID: 3244171 [TBL] [Abstract][Full Text] [Related]
29. [Hyperlipidemia and glomerulosclerosis in nephropathies: clinicomorphological comparisons]. Neverov NI; Ivanov AA Ter Arkh; 1994; 66(7):73-6. PubMed ID: 7985138 [TBL] [Abstract][Full Text] [Related]
30. Atherogenic lipoproteins: mediators of glomerular injury. Kamanna VS; Roh DD; Kirschenbaum MA Am J Nephrol; 1993; 13(1):1-5. PubMed ID: 8322835 [No Abstract] [Full Text] [Related]
31. Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS). Tojo K; Sakai S; Miyahara T Nihon Jinzo Gakkai Shi; 1988 Sep; 30(9):1153-60. PubMed ID: 3216557 [No Abstract] [Full Text] [Related]
32. Glomerulosclerosis: the final pathway is clarified, but can we deal with the triggers? Wardle N Nephron; 1996; 73(1):1-7. PubMed ID: 8742949 [No Abstract] [Full Text] [Related]
34. Modulation of glomerular sclerosis and interstitial fibrosis by native and modified lipoproteins. Gröne HJ; Hohbach J; Gröne EF Kidney Int Suppl; 1996 May; 54():S18-22. PubMed ID: 8731188 [No Abstract] [Full Text] [Related]
35. IgM-associated mesangial proliferative glomerulonephritis and focal and segmental hyalinosis with nephrotic syndrome. Aubert J; Humair L; Chatelanat F; de Torrenté A Am J Nephrol; 1985; 5(6):445-9. PubMed ID: 4083317 [TBL] [Abstract][Full Text] [Related]
36. Focal glomerulosclerosis with cerebral infarction in a young nephrotic patient. Raghu K; Malik AK; Datta BN; Narang A; Mehta S Indian Pediatr; 1981 Oct; 18(10):754-6. PubMed ID: 7327713 [No Abstract] [Full Text] [Related]
37. Cellular biology of glomerulosclerosis. Wardle EN Nephron; 1992; 61(2):125-8. PubMed ID: 1385855 [No Abstract] [Full Text] [Related]
38. Ferritin deposition in the glomerular deposits of focal glomerular sclerosis in the rat. Melcion C; Smith J; Cattell V J Pathol; 1984 Sep; 144(1):45-55. PubMed ID: 6481527 [TBL] [Abstract][Full Text] [Related]
39. The role of altered lipid metabolism in the progression of renal disease: experimental evidence. Keane WF; Kasiske BL; O'Donnell MP; Kim Y Am J Kidney Dis; 1991 May; 17(5 Suppl 1):38-42. PubMed ID: 2024671 [No Abstract] [Full Text] [Related]